WebAbout Abveris. Abveris is a Boston-based, monoclonal antibody discovery contract research organization (CRO). The organization applies proprietary technologies and techniques to develop diverse panels of antibodies on rapid timelines. On November 22nd, 2024, Abveris was acquired by Twist Bioscience at a valuation between $150M and $190M. WebNov 22, 2024 · "The addition of the Abveris discovery platform is a natural fit with Twist as it will complement and extend our biopharma antibody capabilities into mouse-based …
Twist nabs antibody discovery biotech Abveris for $190M a week …
WebAbveris provides high-throughput antibody screening services to discover, characterize, and deliver optimal monoclonal antibodies. We go beyond testing for antibody specificity … WebAbveris applies proprietary antibody discovery technologies and techniques to build platforms to develop diverse panels of antibodies on rapid timelines. ... Twist Bioscience … reddismq
Abveris LinkedIn
WebNov 22, 2024 · On November 22, 2024, Twist Bioscience acquired life science company Abveris for 190M USD. Acquisition Highlights. This is Twist Bioscience’s 2nd transaction in the Life Science sector. This is Twist Bioscience’s largest (disclosed) transaction. This is Twist Bioscience’s 3rd transaction in the United States. WebNov 22, 2024 · All statements other than statements of historical facts contained herein, including but not limited to the closing of the acquisition of Abveris, the successful … WebNov 22, 2024 · "The addition of the Abveris discovery platform is a natural fit with Twist as it will complement and extend our biopharma antibody capabilities into mouse-based discovery and screening," said ... knox county kentucky auditor